Archive for the ‘Research and development’ Category

Emergent BioSolutions to Release Fourth Quarter and Full Year 2010 Financial Results and Conduct a Conference Call on March 10, 2011

ROCKVILLE, Md., Feb 24, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today it will report financial results for the fourth quarter and full year 2010 on Thursday, March 10, 2011, after market close.
Company management will host a conference call at 5:00 pm Eastern on March 10, 2011 to discuss [...]

February 25, 2011  Tags: , , , , ,   Posted in: Biotechnology and Pharmaceuticals, CEO, Emergent BioSolutions, Research and development, fuad el-hibri  No Comments

Emergent BioSolutions Announces Initiation of Phase Ib/II Study of TRU-016 in Combination with Bendamustine for Chronic Lymphocytic Leukemia

ROCKVILLE, Md., Jan 25, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced the initiation of a Phase Ib/II study (16201) of TRU-016 for chronic lymphocytic leukemia (CLL). TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP(TM)) protein therapeutic in development for the treatment of B-cell malignancies. TRU-016 is [...]

February 1, 2011  Tags: , , , , , ,   Posted in: Clinical trial, Emergent BioSolutions, Leukemia, Research and development, fuad el-hibri  No Comments

CEO took roundabout path to Emergent

By Marjorie Censer
Monday, January 3, 2011
Fuad El-Hibri has lived in all sorts of exotic locales, working for Citicorp in Saudi Arabia, consulting for Booz Allen Hamilton in Indonesia and establishing mobile telecommunications businesses in Russia, Venezuela and El Salvador.
But getting started in his current position as chief executive of Rockville-based pharmaceutical company Emergent BioSolutions took [...]

January 7, 2011  Tags: , , , , ,   Posted in: Biosolutions, Business, CEO, Department of Health and Human Services, El-Hibri, Emergent BioSolutions, Research and development, Trubion Pharmaceuticals, Yale University, fuad, fuad el-hibri  No Comments

Emergent BioSolutions Starts Phase I Clinical Trial for Third Generation Anthrax Vaccine

ROCKVILLE, Md., Dec 27, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase I clinical trial for NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), also known as AV7909, with the dosing of the first subject. The product candidate, a third generation vaccine being developed [...]

January 5, 2011  Tags: , , , , ,   Posted in: Anthrax vaccines, Biothrax, Emergent BioSolutions, Health Care, Research and development, United States Department of Health and Human Services, fuad el-hibri  No Comments

Fuad El-Hibri and the International Biomedical Research Alliance

The International Biomedical Research Alliance (IBRA) is a philanthropic organization that is dedicated to the support of the NIH-Oxford-Cambridge Scholars Program, which strives to establish the highest standards of excellence in training biomedical researchers, advance groundbreaking biomedical research, enrich the pool of leaders in the field, and eliminate barriers which frustrate [...]

November 13, 2010  Tags: , , , , , ,   Posted in: Biosolutions, Biothrax, El-Hibri, Emergent BioSolutions, Research and development, fuad el-hibri  No Comments

Emergent BioSolutions Awarded HHS Contract Valued at up to $186.6 Million to Develop rPA Anthrax Vaccine

ROCKVILLE, MD, September 17, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract, valued at up to $186.6 million, with the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), for the development of a recombinant protective antigen [...]

September 20, 2010  Tags: , , , , ,   Posted in: Anthrax vaccines, Biosolutions, Emergent BioSolutions, Research and development, fuad el-hibri  No Comments

Emergent BioSolutions Awarded NIAID Contract That Increases Potential Funding to Over $58 Million for Advanced Development of Third Generation Anthrax Vaccine

New Contract Valued at up to $28.7 Million for Phase II Clinical Trial
ROCKVILLE, Md., Sep 01, 2010 –Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract valued at up to $28.7 million with the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institutes of [...]

September 10, 2010  Tags: , , , , ,   Posted in: Anthrax vaccines, Biothrax, Emergent BioSolutions, Research and development, fuad el-hibri  No Comments

Emergent BioSolutions to Acquire Trubion Pharmaceuticals

Trubion provides promising clinical-stage therapeutic candidates in the targeted disease areas of oncology and autoimmunity
Trubion offers novel, protein therapeutic platforms and scientific expertise for developing innovative therapeutic candidates
Transaction leverages large pharma partnerships to provide sales and marketing infrastructureidates
Emergent reaffirms 2010 guidance for revenues and net income

ROCKVILLE, Md., Aug 12, 2010 (BUSINESS WIRE) –
Emergent BioSolutions Inc. [...]

August 19, 2010  Tags: , , , , , , ,   Posted in: Africa, Anthrax vaccines, Biosolutions, Emergent BioSolutions, Health Care, Management, Research and development, Share, Trubion Pharmaceuticals, fuad el-hibri  No Comments

Emergent BioSolutions Recognized as Biotechnology Firm of the Year by Tech Council of Maryland

ROCKVILLE, MD, May 13, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has been named Biotechnology Firm of the Year at the Tech Council of Maryland’s (TCM) Annual Tech Awards.  This award acknowledges the company that best exemplifies the spirit of Maryland’s biotechnology community as well as its presence and leadership within the [...]

May 18, 2010  Tags: , , , , , ,   Posted in: CEO, Department of Health and Human Services, Emergent BioSolutions, Research and development, Tech Council of Maryland, fuad el-hibri  No Comments